LETTER
Access to 5-Substituted Prolines
1565
spectively. The pyrrolidinium ring shows an envelope
conformation with N(1), C(2), C(4), C(5) defining the
best least-squares plane while C(3) is out-of-plane with a
deviation of 0.59 Å from it. The two substituents, that is,
the carboxylate and the isopentyl chain are in axial and bi-
sectional position, respectively (Figure 1).
Acknowledgment
This work was financially supported by MIUR (Rome, Progetto
PRIN 2006) and the University of Siena (Progetto PAR 2005).
Reference and Notes
(1) For example, search for ‘proline’ in ISI Web of
KnowledgeTM of Thomson Reuters) gives more than 200
reviews in ‘chemistry’ between 2000 and 2008.
(2) Koskinen, A. M. P.; Helaja, J.; Kumpulainen, E. T. T.;
Koivisto, J.; Mansikkamaeki, H.; Rissanen, K. J. Org.
Chem. 2005, 70, 6447; and references therein.
The crystal structure is stabilised by strong intermolecular
hydrogen bonds involving the pyrrolidinium NH2 and
both the oxygen atoms of the carboxylate group.
Starting from compound 28 we designed a convenient
synthetic scheme to prepare the indolizidine amino acid
33, having a structure related to other indolizidines that
have applications as peptidomimetics in medicinal chem-
istry.24 Proline 28 was first protected as the Cbz derivative
and then methylated at the carboxylic group. O-Methyl-
isourea 30, prepared through reaction of commercially
available PS-supported microporous DCC in dry metha-
nol under microwave heating,25 was used for methylation
of the COOH group. Addition of 29 to resin 30 at 60 °C in
dichloromethane gave compound 31 in 75% overall yield
(Scheme 2). The oxazolidine acetonide was then removed
using PPTS in hot ethanol26 to give the proline derivative
32. The terminal OH was transformed into the tosylate
and the product submitted to microwave-assisted transfer
hydrogenation.27 The Cbz group was removed and the free
proline NH underwent intramolecular nucleophilic substi-
tution at the carbon carrying the tosylate to give the
indolizidine amino acid 33 as a single diasteromer as re-
vealed by 1H NMR (400 MHz) and HPLC analyses.
(3) Cheng, X.-C.; Wang, Q.; Fang, H.; Xu, W.-F. Curr. Med.
Chem. 2008, 15, 374.
(4) See, for example: Schardl, C. L.; Grossman, R. B.;
Nagabhyru, P.; Faulkner, J. R.; Mallik, U. P. Phytochemistry
2007, 68, 980; and references therein.
(5) Fournie-Zaluski, M.-C.; Coric, P.; Thery, V.; Gonzales, W.;
Mendal, H.; Turcaud, S.; Michel, J.-B.; Roques, B. P.
J. Med. Chem. 1996, 39, 2594.
(6) Doyle, A. G.; Jacobsen, E. N. Chem. Rev. 2007, 107, 5713.
(7) Rodriquez, M.; Taddei, M. Synthesis 2005, 493.
(8) Rodriquez, M.; Bruno, I.; Cini, E.; Marchetti, M.; Taddei,
M.; Gomez-Paloma, L. J. Org. Chem. 2006, 71, 103.
(9) Mota, A. J.; Langlois, N. Tetrahedron Lett. 2003, 44, 1141.
(10) Knight, D. W.; Redfern, A. L.; Gilmore, J. J. Chem. Soc.,
Perkin Trans. 1 2002, 622.
(11) Davis, F. A.; Zhang, H.; Lee, S. H. Org. Lett. 2001, 3, 759.
(12) van Esseveldt, B. C. J.; van Delft, F. L.; Smits, J. M. M.;
de Gelder, R.; Rutjes, F. P. J. T. Synlett 2003, 2354.
(13) Li, H.; Sakamoto, T.; Kikugawa, Y. Tetrahedron Lett. 1997,
38, 6677.
(14) Rudolph, A. C.; Machauer, R.; Martin, S. F. Tetrahedron
Lett. 2004, 45, 4895.
(15) Dietrich, E.; Lubell, W. D. J. Org. Chem. 2003, 68, 6988.
(16) Beausoleil, E.; L’Archeveque, B.; Belec, L.; Atfani, M.;
Lubell, W. D. J. Org. Chem. 1996, 61, 9447.
(17) (S)-2-Dibenzylamino-6-(dimethoxyphosphoryl)-5-
oxohexanoic Acid Benzyl Ester (5)
30, THF, MW
CbzCl, Et3N
CH2Cl2
Boc
N
80 °C, 2 min
HOOC
N
28
90%
84%
Cbz
29
Boc
O
PPTS, EtOH,
To a soln of dimethyl methylphosphonate (0.191 g, 1.54
mmol) in dry THF (17 mL) cooled at –78 °C, BuLi (0.62 mL
of a 2.5 M soln in hexane) was added dropwise. After 40
min, a soln of 4 (0.390 g, 7.7 mmol) in dry THF (14 mL) was
added. After stirring for 4 h at –78 °C, a sat. soln of NH4Cl
(6 mL) was added followed by EtOAc (30 mL). After
warming to r.t., the organic phase was separated. The
aqueous phase was extracted with EtOAc, all the organic
fractions were collected and dried over Na2SO4. The solvent
was removed in vacuo, and the crude material was purified
by column chromatography (PE–EtOAc, 1:3) to give
compound 5 as colourless oil (0.26 g, 65% yield). 1H NMR
(400 MHz, CDCl3): d = 1.95–2.02 (m, 2 H, H-3), 2.41–2.78
(m, 2 H, H-4), 2.79–2.97 (m, 2 H, H-6), 3.29 (t, J = 6.8 Hz,
1 H, H-2), 3.67 (AB system, 4 H, NCH2Ph), 3.68 (d, J = 2.8
Hz, 3 H, OCH3), 3.71 (d, J = 2.8 Hz, 3 H, OCH3), 5.19 (AB
system, 2 H, OCH2Ph), 7.19–7.36 (m, 15 H, ArH). 13C NMR
(50 MHz, CDCl3): d = 22.6, 40.0, 40.4, 42.5, 52.8, 53.0,
54.4, 59.8, 66.1, 127.1 54.5, 59.8, 66.2, 127,1, 128.2, 128.3,
128.5, 128.6, 128.9, 135.9 (2 C), 139.21, 172.13, 200.7,
200.8. HRMS (ES): m/z calcd for C29H35NO6P [M + H]+:
524.2202; found: 524.2180.
MeOOC
60 °C, 12 h
N
N
71%
Cbz
31
O
1) TsCl, pyridine, r.t.
2) HCOONH4, Pd/C
i-PrOH, MW, 10 min
MeOOC
N
N
NHBoc
NHBoc
54%
Cbz
32
MeOOC
33
HO
Scheme 2 Preparation of indolizidine amino acid 31
Compound 33 has the two functional groups orthogonally
protected and it is in a suitable form to be inserted into a
peptide sequence.
In conclusion we have developed a convenient approach
to enantiomerically pure cis-5-substituted prolines that
can be applied to differently functionalised substrates
(apart alkenes or alkyl halides). The resulting prolines can
be used as modified amino acids, potential organocata-
lysts soluble in low polarity organic solvents or as starting
material for the preparation of indolizidine alkaloids or
peptidomimetics.
(18) Petricci, E.; Mann, A.; Rota, A.; Schoenfelder, A.; Taddei,
M. Org. Lett. 2006, 8, 3725.
(19) For the domino hydroformylation–Wittig reaction, see:
(a) Breit, B.; Zhan, S. K. Angew. Chem. Int. Ed. 1999, 38,
969. (b) Breit, B.; Zhan, S. K. Tetrahedron 2005, 61, 6171.
Synlett 2009, No. 10, 1562–1566 © Thieme Stuttgart · New York